Diadema Partners LP Summit Therapeutics Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Diadema Partners LP holds 20,000 shares of SMMT stock, worth $461,200. This represents 0.15% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$461,200% of portfolio
0.15%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$563 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$269 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$151 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$129 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...